SCHEMBL3874437

SCHEMBL3874437

CCCOC(=O)c1cc(C(=O)O)c2cc(Cc3ccc(F)cc3)cnc2c1O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.35
LTB4R Q15722 1/20 0.35
LTB4R2 Q9NPC1 1/20 0.35
POLB P06746 1/20 0.34
TP53 P04637 1/20 0.34
PDE4B Q07343 1/20 0.33
MAOB P27338 1/20 0.33
EIF4A1 P60842 1/20 0.33
KDM4E B2RXH2 1/20 0.33
GAA P10253 1/20 0.33
MAPT P10636 1/20 0.33
ATM Q13315 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
GRM2 Q14416 1/20 0.33
PDE3B Q13370 1/20 0.33
PDE3A Q14432 1/20 0.33
KDM5A P29375 1/20 0.33
KDM4C Q9H3R0 1/20 0.33
KDM5B Q9UGL1 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3877680 0.92 MAPT (0.40) ALDH1A1POLBPDE4BMAOBKDM4E
SCHEMBL3868271 0.91 KDM4E (0.38) ALDH1A1POLBTP53KDM4EGAA
SCHEMBL3867709 0.88 MAPT (0.43) ALDH1A1KDM4EGAAMAPTNPSR1
Alcohol SCHEMBL3867585 0.87 MAPT (0.41) ALDH1A1PDE4BKDM4EGAAMAPT
SCHEMBL3870147 0.87 MAPT (0.42) ALDH1A1KDM4EGAAMAPTNPSR1
SCHEMBL3866778 0.87 MAPT (0.42) ALDH1A1KDM4EGAAMAPTNPSR1
SCHEMBL3870135 0.87 MAPT (0.42) ALDH1A1KDM4EGAAMAPTNPSR1
Potassium SCHEMBL3869495 0.87 MAPT (0.42) ALDH1A1KDM4EGAAMAPTNPSR1
SCHEMBL3869489 0.87 MAPT (0.42) ALDH1A1KDM4EGAAMAPTNPSR1
SCHEMBL3866785 0.87 MAPT (0.42) ALDH1A1KDM4EGAAMAPTNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090118233-A1 Heterocyclic compounds having inhibitory activity against HIV integrase MURAI HITOSHI 2009-05-07 US disclosed
EP-2045242-A1 Heterocyclic compounds having inhibitory activity against HIV integrase Shionogi&Co., Ltd. (JP) 2009-04-08 EP disclosed
EP-1541558-B1 HETEROCYCLIC COMPOUNDS HAVING HIV INTEGRASE INHIBITORY ACTIVITY SHIONOGI & CO (JP) 2008-08-13 EP disclosed
US-7358249-B2 Heterocyclic compounds having inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2008-04-15 US disclosed
US-20060247212-A1 Heterocyclic compounds having inhibitory activity against HIV integrase MURAI HITOSHI 2006-11-02 US disclosed
US-20060128669-A1 Heterocyclic compounds having inhibitory activity against hiv integrase SHIONOGI & CO., LTD. (JP) 2006-06-15 US disclosed
EP-1541558-A1 HETEROCYCLIC COMPOUND HAVING HIV INTEGRASE INHIBITORY ACTIVITY SHIONOGI & CO., LTD. (JP) 2005-06-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090118233-A1 Heterocyclic compounds having inhibitory activity against HIV integrase CYP3A7, CDK7, CYP2A7 ALDH1A1 381/4885LTB4R 2165/4885LTB4R2 2453/4885
US-20060247212-A1 Heterocyclic compounds having inhibitory activity against HIV integrase CYP3A7, CDK7, CYP2A7 ALDH1A1 370/4885LTB4R 2179/4885LTB4R2 2484/4885
US-20060128669-A1 Heterocyclic compounds having inhibitory activity against hiv integrase CYP3A7, CDK7, CYP2A7 ALDH1A1 381/4885LTB4R 2165/4885LTB4R2 2453/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.